2-甲基-1-丙基-1H-苯并咪唑 | 5805-77-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-甲基-1-丙基-1H-苯并咪唑
• 英文名称: 1-n-propyl-2-methyl-benzimidazole
• 英文别名: 2-methyl-1-propyl-1H-benzimidazole；2-Methyl-1-propyl-1H-benzimidazol；2-methyl-1-propyl-1H-benzo[d]imidazole；2-Methyl-1-propyl-1H-benzimidazole；2-methyl-1-propylbenzimidazole
• CAS: 5805-77-6
• 化学式: C₁₁H₁₄N₂
• mdl: MFCD01051240
• 分子量: 174.246
• InChiKey: OBOYYFMVZPXZNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-甲基苯并咪唑 、 1-碘代丙烷 在 氢氧化钾 作用下， 以 丙酮 为溶剂， 反应 3.0h， 以88%的产率得到2-甲基-1-丙基-1H-苯并咪唑
  参考文献：
  名称：

  WO2008/6236

  摘要：

  公开号：

文献信息

• [EN] ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE ALPHA-AMINO BORONIQUE, INHIBITEURS SÉLECTIFS DE L'IMMUNOPROTÉASOME
  申请人：ARES TRADING SA

  公开号：WO2013092979A1

  公开（公告）日：2013-06-27

  The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases. In formula (I), Rb and Rc are independently selected from one another from H or C1-C6-alkyl; whereby Rb and Rc may be linked to form a 5 or 6 membered-ring containing the oxygen atoms to which they are linked; Q denotes Ar, Het or cycloalkyl; R1 R2 independently from each other denotes H, ORa, Hal, C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; Y denotes CR 3R4, preferably CH2 or C(CH3)2; R 3, R4 independently of one another denote H or C1-C6-alkyl; L denotes L1 or L2 or alkyl; n is an integer selected from 0 to 3; L 1 is Q1-CO-M- wherein Q 1 is Ar or Het, preferably, phenyl, naphthyl or pyridine, optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; L2 is Q2-M- wherein Q 2 is a fused bicyclic system containing 1 nitrogen atom and 1 to 3 additional groups independently selected from O, S, N, or CO, and wherein at least one of the rings is aromatic whereby the fused bicyclic system is optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; or Q 2 is unsaturated or aromatic 5 membered-ring system containing 1 to 3 heteroatoms selected from N, O, S and CO, and optionally substituted with a phenyl ring or pyridine ring whereby phenyl ring and pyridine ring are optionally substituted with 1 to 4 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; M is a linear or branched alkylene having 1 to 5 carbon atoms wherein 1 or 2 H atoms may be replaced by OR a or a phenyl ring optionally substituted with 1 to 5 groups independently selected from Hal, ORa, and C1-C6-alkyl optionally substituted with 1 to 5 groups independently selected from OH, and Hal; or M denotes a cycloalkylene having 3 to 7 carbon atoms; or M denotes a thiazolidinyl group; R a is H or C1-C6-alkyl wherein 1 to 5 H atom may be independently replaced by OH or Hal; Ar denotes a 6 membered-aromatic carbocyclic ring optionally fused with another carbocyclic saturated, unsaturated or aromatic ring having 5 to 8 carbon atoms; Het denotes a 5- or 6-membered saturated, unsaturated or aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from N, N+O-, O, S, SO, and SO 2, and optionally fused with another saturated, unsaturated or aromatic ring having 5 to 8 atoms and optionally containing 1 to 3 heteroatoms selected from N, O, and S; Hal denotes CI, Br, I of F; preferably CI or F.

  本发明提供了化合物的公式（I）作为LMP7的抑制剂，用于治疗自身免疫和炎症性疾病。在公式（I）中，Rb和Rc分别独立地从H或C1-C6-烷基中选择；其中Rb和Rc可以连接形成一个含有它们连接的氧原子的5或6元环；Q表示Ar，Het或环烷基；R1和R2彼此独立地表示H，ORa，Hal，C1-C6-烷基，其中1到5个H原子可以独立地被OH或Hal替换；Y表示CR 3R4，优选CH2或C(CH3)2；R3，R4彼此独立地表示H或C1-C6-烷基；L表示L1或L2或烷基；n是从0到3选择的整数；L1是Q1-CO-M-，其中Q1是Ar或Het，优选苯基，萘基或吡啶基，可选地取代为1到5个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；L2是Q2-M-，其中Q2是含有1个氮原子和1到3个额外基团的融合双环系统，独立选择自O，S，N或CO，其中至少一个环是芳香环，融合双环系统可选地取代为1到5个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；或Q2是不饱和或芳香的含有1到3个从N，O，S和CO中选择的杂原子的5元环系统，并可选地取代为苯环或吡啶环，其中苯环和吡啶环可选地取代为1到4个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；M是具有1到5个碳原子的线性或支链烷基，其中1或2个H原子可以被ORa或可选地取代为1到5个从Hal，ORa和C1-C6-烷基中独立选择的基团，可选地取代为1到5个从OH和Hal中独立选择的基团；或M表示具有3到7个碳原子的环烷基；或M表示噻唑烷基；Ra是H或C1-C6-烷基，其中1到5个H原子可以独立地被OH或Hal替换；Ar表示一个6元芳香碳环，可选地与另一个含有5到8个碳原子的碳环饱和、不饱和或芳香环融合；Het表示一个含有1到3个从N，N+O-，O，S，SO和SO2中独立选择的杂原子的5或6元饱和、不饱和或芳香杂环，可选地与另一个含有5到8个原子的饱和、不饱和或芳香环融合，并可选地含有1到3个从N，O和S中选择的杂原子；Hal表示CI，Br，I或F；优选CI或F。
• Sulfonato-Cu(salen) Complex Catalyzed N-Arylation of Aliphatic Amines with Aryl Halides in Water
  作者：Zhiqing Wu、Li Zhou、Zhaoqiong Jiang、Di Wu、Zhengkai Li、Xiangge Zhou

  DOI：10.1002/ejoc.201000840

  日期：2010.9

  catalyzed procedure for the N-arylation of simple aliphatic amines, amino alcohols and amino acids in pure water have been developed. A variety of substituted aryl iodides, bromides and electron-deficient chlorides were found to be applicable, and 1,2-disubstituted benzimidazoles could be prepared easily by a cascade amination/condensation process in this catalytic system.

  已开发出一种水溶性磺酸根-Cu(salen) 络合物催化方法，用于在纯水中对简单脂肪胺、氨基醇和氨基酸进行 N-芳基化。发现各种取代的芳基碘化物、溴化物和缺电子氯化物是适用的，并且在该催化体系中通过级联胺化/缩合过程可以很容易地制备 1,2-二取代苯并咪唑。
• LIGAND EXCHANGE THERMOCHROMIC SYSTEMS AND HIGH E LIGANDS FOR SAME
  申请人：Byker J. Harlan

  公开号：US20080105851A1

  公开（公告）日：2008-05-08

  Ligand exchange of thermochromic, LETC, systems exhibiting a reversible change in absorbance of electromagnetic radiation as the temperature of the system is reversibly changed are described. The described LETC systems include one or more than one transition metal ion, which experiences thermally induced changes in the nature of the complexation or coordination around the transition metal ion(s) and, thereby, the system changes its ability to absorb electromagnetic radiation as the temperature changes. In accordance with certain aspects of the present invention, a thermochromic system is disclosed comprising a transition metal ion and a ligand wherein the ligand comprises a nitrogen-containing five or six membered heterocyclic compound that coordinates through the nitrogen atom to the transition metal ion in a HεMLC formed between the transition metal ion and the ligand. In accordance with other aspects of the present invention, thermochromic systems are disclosed comprising a transition metal ion with particularly useful ligands, such as phosphine compounds, tridentate ligands that coordinate through three nitrogen atoms, bidentate ligands, or ortho hindered pyridine monodentate ligands.

  本文描述了具有热致变色性质的配体交换（LETC）系统，当系统的温度可逆变化时，电磁辐射吸收率也可逆变化。所述的LETC系统包括一个或多个过渡金属离子，其经历热诱导的配位或配位环境的变化，从而使系统随着温度变化而改变吸收电磁辐射的能力。根据本发明的某些方面，公开了包括过渡金属离子和配体的热致变色系统，其中配体包括通过氮原子与过渡金属离子形成的HεMLC（配体与过渡金属离子之间的配位键）的含氮五元或六元杂环化合物。根据本发明的其他方面，公开了包括具有特别有用的配体的过渡金属离子的热致变色系统，例如膦化合物、通过三个氮原子配位的三齿配体、双齿配体或邻位受阻的吡啶单齿配体。
• LIGAND EXCHANGE THERMOCHROMIC SYSTEMS CONTAINING EXCHANGE METALS
  申请人：Byker J. Harlan

  公开号：US20080106781A1

  公开（公告）日：2008-05-08

  Ligand exchange of thermochromic, LETC, systems exhibiting a reversible change in absorbance of electromagnetic radiation as the temperature of the system is reversibly changed are described. The described LETC systems include one or more than one transition metal ion, which experiences thermally induced changes in the nature of the complexation or coordination around the transition metal ion(s) and, thereby, the system changes its ability to absorb electromagnetic radiation as the temperature changes. In accordance with one aspect of the present invention, a thermochromic system is disclosed comprising a first metal ion and a second metal ion and at least one ligand that complexes with the first metal ion to form a LεMLC and complexes with the second metal ion to form a HεMLC wherein an increase in temperature of the system results in a reversible net increase in its ability to absorb light energy in the 400 nm to 1400 nm range due to the ligand transferring from the first metal ion to the second metal ion.

  本文介绍了一种具有热致变色特性的配体交换系统，当系统的温度可逆变化时，其吸收电磁辐射的能力也可逆变化。所述的LETC系统包括一个或多个过渡金属离子，其在过渡金属离子周围的络合或配位发生热诱导变化，从而使系统随着温度变化而改变吸收电磁辐射的能力。根据本发明的一个方面，公开了一种热致变色系统，包括第一金属离子和第二金属离子以及至少一个配体，该配体与第一金属离子形成LεMLC配合物，并与第二金属离子形成HεMLC配合物，系统温度的升高导致可逆的净吸收光能力增加，范围为400纳米至1400纳米，这是由于配体从第一金属离子转移到第二金属离子造成的。
• LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS
  申请人：Byker J. Harlan

  公开号：US20080100902A1

  公开（公告）日：2008-05-01

  Ligand exchange of thermochromic, LETC, systems exhibiting a reversible change in absorbance of electromagnetic radiation as the temperature of the system is reversibly changed are described. The described LETC systems include one or more than one transition metal ion, which experiences thermally induced changes in the nature of the complexation or coordination around the transition metal ion(s) and, thereby, the system changes its ability to absorb electromagnetic radiation as the temperature changes.

  本文介绍了一种热致变色（LETC）系统的配体交换方法，该系统在温度可逆变化时显示出电磁辐射吸收的可逆变化。所述LETC系统包括一个或多个过渡金属离子，其在过渡金属离子周围的配位或络合性质发生热诱导变化，从而使系统在温度变化时改变吸收电磁辐射的能力。